Ardelyx Inc. Shares Surge Past 200-Day Moving Average, Trading Up 14.2%
ByAinvest
Tuesday, Aug 5, 2025 12:10 pm ET1min read
ARDX--
The move comes as Ardelyx Inc reported its Q2 2025 earnings, which exceeded analysts’ expectations. The company posted a net loss of $0.08 per share, beating the forecasted $0.13 loss. Revenue reached $97.7 million, surpassing the forecast of $82.51 million, representing an 18.41% surprise [2].
The company’s strong performance is driven by the success of its key products, IBSRELA and EXPOSA. IBSRELA net sales grew by 84% year-over-year, while EXPOSA net sales increased by 7% quarter-over-quarter. Ardelyx has also raised its full-year revenue guidance for IBSRELA to $250-$260 million, signaling optimism about sustained demand [2].
The stock remains below its 52-week high of $7.18 but is significantly above its 52-week low of $3.21. While the stock has experienced a -21.56% return over the past six months, the modest stock movement reflects investor confidence in the company’s performance and future prospects [2].
References:
[1] https://www.nasdaq.com/articles/ardelyx-ardx-shares-cross-above-200-dma
[2] https://za.investing.com/news/transcripts/earnings-call-transcript-ardelyx-q2-2025-beats-earnings-expectations-93CH-3818942
Ardelyx Inc (ARDX) shares have crossed above their 200-day moving average of $4.87, reaching $5.49 per share. The stock is up 14.2% on the day, with a 52-week low of $3.21 and a high of $7.18.
Ardelyx Inc (ARDX) shares have crossed above their 200-day moving average of $4.87, reaching $5.49 per share. The stock is up 14.2% on the day, with a 52-week low of $3.21 and a high of $7.18 [1].The move comes as Ardelyx Inc reported its Q2 2025 earnings, which exceeded analysts’ expectations. The company posted a net loss of $0.08 per share, beating the forecasted $0.13 loss. Revenue reached $97.7 million, surpassing the forecast of $82.51 million, representing an 18.41% surprise [2].
The company’s strong performance is driven by the success of its key products, IBSRELA and EXPOSA. IBSRELA net sales grew by 84% year-over-year, while EXPOSA net sales increased by 7% quarter-over-quarter. Ardelyx has also raised its full-year revenue guidance for IBSRELA to $250-$260 million, signaling optimism about sustained demand [2].
The stock remains below its 52-week high of $7.18 but is significantly above its 52-week low of $3.21. While the stock has experienced a -21.56% return over the past six months, the modest stock movement reflects investor confidence in the company’s performance and future prospects [2].
References:
[1] https://www.nasdaq.com/articles/ardelyx-ardx-shares-cross-above-200-dma
[2] https://za.investing.com/news/transcripts/earnings-call-transcript-ardelyx-q2-2025-beats-earnings-expectations-93CH-3818942
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue

Comments
No comments yet